Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — FY2021 Earnings Presentation
26 slides from Lumos Diagnostics's earnings presentation, Aug 30, 2021
Slide 1: FY21 Results Briefing
Lumos Diagnostics Holdings Limited FY21 Results Briefing 30 August 2021 © Lumos Diagnostics, all rights reserved www.lumosdiagnostics.com LUMOS DIAGNOSTICS 1 FY21 RESULTS BRIEFING
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “
Slide 3: Lumos Diagnostics (ASX:LDX)
Lumos Diagnostics (ASX:LDX) © Lumos Diagnostics, all rights reserved LUMOS DIAGNOSTICS 3 FY21 RESULTS BRIEFING
Slide 4: FY21 At A Glance
FY21 At A Glance A$25.0M total revenue in FY21 198% YoY increase “ While FY20 was all about integration and A$22.7M Commercial Services business unit revenue in FY21 188% YoY increase transformation, FY21 represented strategic action and growth. Global manufacturing capacity expanded up to 10 millio
Slide 5: Company Overview
Company Overview LUMOS DIAGNOSTICS 5 FY21 RESULTS BRIEFING
Slide 6: About Lumos
About Lumos (A$ in millions) Our Mission KEY COMPANY DATA SHARE REGISTER BREAKDOWN Share Price1 Shares on Issue Market Cap1 Cash Balance2 Institutions Corporate Retail To develop, $1.20 150M $186.0M $59.7M 38% 37% 25% manufacture and provide access to rapid, accurate and actionable diagnostic soluti
Slide 7: Lumos Business Model
Lumos Business Model Lumos is a fully integrated innovator, developer and manufacturer of rapid POC diagnostic solutions that allow clinicians and patients to make important medical decisions quickly and accurately. GLOBAL POC DIAGNOSTIC TEST SALES1 (US$ in billions) US$50B 50 40 US$30B 30 20 reserv
Slide 8: Products Business Unit
Products Business Unit LUMOS DIAGNOSTICS 8 FY21 RESULTS BRIEFING
Slide 9: Product Business Operating Highlights
Product Business Operating Highlights • Revenue of A$2.3M from product sales, up significantly from FY20 • Majority of product revenues from sale of FebriDx® in the UK, Germany and Canada - Limited ability to target primary care users during FY21 due to COVID-19 restrictions - Offset by opportunisti
Slide 10: A Validated Rapid Test for Microbial Infection
: A Validated Rapid Test for Microbial Infection FebriDx U.S. CLINICAL EVALUATION FOR FEBRILE PATIENTS PRESENTING WITH SYMPTOMS AND SIGNS OF ARI 2 Sensitivity 95% Bacterial Specificity 91% BACTERIAL INFECTION VIRAL INFECTION VIRAL INFECTION NPV 97% Sensitivity 77% Can treat patient Antibiotics will
Slide 11: FebriDx Path to Commercialisation in the U.S.
FebriDx® Path to Commercialisation in the U.S. • U.S. commercial launch in FY22 pending U.S. FDA 510(k) clearance • Initial launch focus on the US$500M+ specialty outpatient markets not reliant on reimbursement - Developed a hybrid sales strategy based on immediate direct and future distribution sal
Slide 12: Large U.S. Market Opportunity
: Large U.S. Market Opportunity ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE ANTIBIOTICS PRESCRIBED Common cold Sinusitis 260M antibiotic prescriptions issued in outpatient settings each year3 Other infections Bronchitis Sore throat 44% of antibiotic prescriptions are written to treat patients with AR
Slide 13: Rapid COVID-19 Antigen Test Solution
: Rapid COVID-19 Antigen Test Solution SIMPLE TEST PROCEDURE RESULTS IN 15 MINUTES STRONG U.S. CLINICAL DATA AGAINST HIGH SENSITIVITY PCR • Initial sales commenced into Europe CoviDx Results vs. RT-PCR • Launch in the U.S., Canada and Australia in PCR Test FY22 pending regulatory approvals CoviDx-
Slide 14: Promising Product Pipeline
Promising Product Pipeline Lumos is leveraging its expertise and infrastructure to expand the Lumos-branded family of POC diagnostic tests and readers. Lumos has a growing portfolio of POC diagnostic solutions for healthcare providers in a variety of care settings. Diagnostics,all LumosDiagnostics,
Slide 15: Commercial Services Business Unit
Commercial Services Business Unit LUMOS DIAGNOSTICS 15 FY21 RESULTS BRIEFING
Slide 16: Commercial Services Operating Highlights
Commercial Services Operating Highlights • Record revenue of A$22.7M in FY21, up 188% from FY20 • Success winning contracts with new and existing clients - Won 30 contracts spanning 10 development programs in FY21 • Strong demand for POC diagnostic tests R&D services continues - Non-COVID and COVID-
Slide 17: Financial Results Overview
Financial Results Overview LUMOS DIAGNOSTICS 17 FY21 RESULTS BRIEFING
Slide 18: FY21 Profit & Loss
FY21 Profit & Loss (A$ in millions) FY21 RESULTS vs FORECAST (PRO FORMA) COMMENTARY FY19A FY20A FY21A Prospectus Variance Product revenue 0.2 0.5 2.3 2.9 (0.6) Services revenue 6.2 7.9 22.7 20.9 1.8 Revenue 6.5 8.4 25.0 23.8 1.2 1 Cost of sales (4.2) (5.2) (13.7) (12.5) (1.2) Gross Profit 2.3 3.2 11
Slide 19: FY21 Revenue
FY21 Revenue (A$ in thousands) GROUP REVENUES (STATUTORY) GROUP REVENUES (HALF YEAR) REVENUE MIX BY BUSINESS SEGMENT © Lumos Diagnostics, all rights reserved COMMENTARY A record year Strong demand for services during FY21 • Lumos reporting group revenues of A$25.0M, up $198% on FY20 • High demand fr
Slide 20: FY21 Margin, OPEX & EBITDA
FY21 Margin, OPEX & EBITDA (A$ in thousands) GROSS MARGIN (PRO FORMA)1 OPERATING EXPENSES (PRO FORMA) EBITDA (PRO FORMA) © Lumos Diagnostics, all rights reserved COMMENTARY Gross margin evolving with revenue mix Investment in growth and operations • Ahead of prospectus forecast • Actual EBITDA ahead
Slide 21: FY21 Cash Flows
FY21 Cash Flows (A$ in millions) CONSOLIDATED PRO FORMA HISTORICAL CASH FLOWS, PRO FORMA PROSPECTUS CASH FLOWS COMMENTARY • Underlying EBITDA improvement over forecast ($0.5M) due to higher revenues and lower than anticipated operating FY19A FY20A FY21A Prospectus Variance expenditure in prospectus
Slide 22: Balance Sheet
Balance Sheet (A$ in millions) Statutory Statutory 30 June 2020 30 June 2021 COMMENTARY Assets Current assets Cash and cash equivalents 1.2 59.7 • Cash balance of $59.7M reflects IPO proceeds of $38.0M inclusive of $25.0M reserved Trade and other receivables 1.4 5.7 for sell-down related to the IPO.
Slide 23: FY22 Outlook
FY22 Outlook “ Solid, diversifying revenue mix in FY22 driven by expansion of product business and contract manufacturing Lumos is well positioned as an emerging technology Broader engagement with clients as a result of expanded Commercial Services offerings leader in the rapidly growing global POC
Slide 24: FY22 Milestones & Achievements
FY22 Milestones & Achievements • U.S. FDA 510(k) clearance: FebriDx® • DISRUPT clinical trial data in high impact • U.S. Emergency Use Authorization (EUA): peer reviewed publications CoviDx™ and ViraDx™ • FebriDx U.S. cost analysis in high impact • Health Canada Interim Order (IO): Regulatory Medica
Slide 25: Q&A
Q&A © Lumos Diagnostics, all rights reserved LUMOS DIAGNOSTICS 25 FY21 RESULTS BRIEFING
Slide 26: © Lumos Diagnostics, all rights reserved
© Lumos Diagnostics, all rights reserved www.lumosdiagnostics.com LUMOS DIAGNOSTICS 26 FY21 RESULTS BRIEFING
Lumos Diagnostics Holdings — FY2021 Earnings Presentation on 6ix